Press Releases
Please view the latest press from Enzo Biochem, Inc.
Date | Details |
Monday, December 13, 2010 | ENZO Biochem Announces First Quarter Results Company Generates Positive EBITDA, Improving $2.9 Million Sequentially; Recent Actions to Streamline Operations Begin To Drive Results |
Tuesday, December 07, 2010 | ENZO Biochem Schedules Teleconference to Discuss Fiscal First Quarter Results on December 13, 2010, at 8:30AM E.T. |
Friday, November 19, 2010 | 2010 Annual Report and Proxy Materials |
Wednesday, November 10, 2010 | ENZO Biochem To Present At Lazard Capital Markets 7th Annual Healthcare Conference |
Friday, October 15, 2010 | ENZO Biochem Schedules Teleconference to Discuss 2010 Fourth Quarter and Year-End Results on October 15, 2010, At 8:30 Am E.T. |
Thursday, October 14, 2010 | ENZO Biochem Reports Fourth Quarter and Year End Results Recent Initiatives to Generate Cost Savings In Excess Of $4 Million and Target Positive Cash-Flow from Operations In 2011 |
Monday, October 04, 2010 | Enzo Biochem Initiates Clinical Trial for Treatment of Uveitis at NIH Study of Optiquel™, a Proprietary Therapeutic to be Conducted By the National Institute of Health’s National Eye Institute |
Monday, September 20, 2010 | Enzo Biochem Streamlines Operations; Expects Positive Operating Cash Flow in 2011 |
Wednesday, September 08, 2010 | ENZO Biochem to Present at Two Healthcare Conferences in New York City |
Thursday, August 26, 2010 | ENZO Biochem’s Clinical Lab Takes Major Step In Becoming National Provider of Predictive Diagnostics Pennsylvania Grants Lab License to Operate, With Several Others Pending |
Monday, August 02, 2010 | ENZO Biochem’s Clinical Labs Unit Named a Participant In Empire Bluecross Blueshield Provider Network |
Wednesday, June 09, 2010 | ENZO Biochem Reports Third Quarter Operating Results |
Monday, June 07, 2010 | ENZO Biochem to Present at 9th Annual Needham Healthcare Conference |
Monday, June 07, 2010 | ENZO Biochem Schedules Teleconference to Discuss Third Quarter 2010 Results for June 10, 2010, At 8:30 AM E.T. |
Wednesday, May 19, 2010 | ENZO Biochem’s Clinical Labs Unit Enters Into Co-Marketing |
Monday, May 17, 2010 | United States Board of Patent Appeals Denies Siemens Healthcare Diagnostics' Request For Rehearing on Enzo’s Pending Universal Interference Patent |
Monday, March 29, 2010 | ENZO Biochem Says Favorable Patent Appeals Court Decision Will Allow Pursuit of Claim for Substantial Damages |
Wednesday, March 17, 2010 | ENZO Biochem Announces Supply and Distribution Agreement with Cancer Genetics Enzo Fluorescent Dye Labels To Be Incorporated With CGI’s DNA Fish Probes |
Monday, March 15, 2010 | ENZO Biochem’s Clinical Lab Division Enters Exclusive Agreement With Novel Sequencing Provider Multigen Diagnostics, Inc. Enzo’s Third Molecular Diagnostics Agreement Provides Access to Multiplex Sequencing Technology |
Friday, March 12, 2010 | ENZO Biochem Reports Results for Second Fiscal Quarter Revenues Increase 11%; Gross Profit Up 36%; Gross Margin Increases 24% |
Wednesday, March 10, 2010 | ENZO Biochem Schedules Teleconference to Discuss Second Quarter 2010 Results for March 15, 2010, At 8:30 AM E.T. |
Thursday, March 04, 2010 | ENZO Biochem Names Robert Boorstein, MD, PHD, Medical Director of Enzo Clinical Labs |
Monday, March 01, 2010 | ENZO Biochem Announces Favorable Judgment by U.S. Patent Office in an Interference Against Bayer Healthcare For A Universal Diagnostic Detection System |
Friday, January 29, 2010 | ENZO Biochem Is Well Positioned For New Paradigms In Biotech and Healthcare, Annual Meeting Is Told Company Nominees for Class I Directors Approved By Shareholders |
Wednesday, January 13, 2010 | ENZO Biochem Reports That Its Clinical Labs Division Has Available Newly Authorized Swine Flu (H1n1) Test |